Advice

in the absence of a submission from the holder of the marketing authorisation:

pembrolizumab (Keytruda®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice361KB (PDF)

Download

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2143
Indication:
As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy.
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
10 December 2018